Arrowhead Pharmaceuticals Inc

Financials

Flusso di cassa derivante dalle attività operative -95.39 M171.22 M-136.13 M-153.89 M-462.85 M179.55 M 339.31 M Flussi di cassa derivanti dalle attività di investimento -240.78 M-141.68 M-5.42 M-96.16 M-420.07 M-129.29 M -229.95 M Liquidità derivante dalle attività di finanziamento 257.95 M11.3 M65.19 M253.05 M870.52 M74.01 M 38.62 M Liquidità libera -107.34 M147.66 M-188.91 M-330.63 M-604.32 M156.89 M 322.01 M

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

ARWR

Financials

Arrowhead Pharmaceuticals Inc

Notizie

TD Cowen conferma rating Buy su Arrowhead Pharma

BofA riduce il target di prezzo di Arrowhead Pharma per l’obesità

Wave Life Sciences Crashes 55% As 'Body Composition' Fat-Loss Drug Underwhelms

Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead (NASDAQ:ARWR)

Leerink conferma il rating su Arrowhead Pharma dopo i dati del partner

Wolfe Research conferma il rating su Ionis per la strategia di prezzo

Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies

SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study

Hamilton James, CMO di Arrowhead Pharmaceuticals, vende azioni per 641.900 dollari

Arrowhead Pharmaceuticals alla Conferenza Leerink: Approfondimenti Strategici sulla Pipeline

Arrowhead Pharmaceuticals at Leerink Conference: Strategic Pipeline Insights

Arrowhead Pharmaceuticals alla TD Cowen Conference: focus cardiometabolico